- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06466369
Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia
June 14, 2024 updated by: ahmed salah saad abomandour, Al-Azhar University
Efficacy and Safety of Once Daily Administration Tadalafil in Patients With Benign Prostatic Hyperplasia
The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
306
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- outpatient clinic of the urology department at AlZahraa University Hospital, Al-Azhar University, Faculty of Medicine for Girls.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged ≥ 45 years and sexually active with symptomatic benign prostatic hyperplasia (no hospitalization 3 months prior to start of treatment).
Exclusion Criteria:
- 1. Patients with bladder or prostate malignancy. 2. A history of lower urinary tract surgery. 3. History of catheterization. 4. Urinary retention. 5. Urinary tract infection. 6. Stone disease. 7. Any neurological disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Controlled group
|
|
Experimental: Low-dose intervention group
|
tadalafil 2.5 mg, 5 mg
|
Experimental: High-dose intervention group
|
tadalafil 2.5 mg, 5 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of International prostate symptom score (IPSS)/quality of life (QoL).
Time Frame: 3 months compared to baseline
|
3 months compared to baseline
|
Evaluation of International index of erectile function (IIEF).
Time Frame: 3 months compared to baseline
|
3 months compared to baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2024
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
June 14, 2024
First Submitted That Met QC Criteria
June 14, 2024
First Posted (Actual)
June 20, 2024
Study Record Updates
Last Update Posted (Actual)
June 20, 2024
Last Update Submitted That Met QC Criteria
June 14, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urological Manifestations
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Lower Urinary Tract Symptoms
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Tadalafil
Other Study ID Numbers
- 416
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BPH With Other Lower Urinary Tract Symptoms
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterUnknownPain | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States
-
BE Technologies IncUrology of VirginiaCompletedOveractive Bladder | Lower Urinary Tract Symptoms | Urinary Incontinence, Urge | Overactive Bladder Syndrome | BPH | Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms | BPH Without Urinary Obstruction | BPH Without Urinary Obstruction With Other Lower Urinary...United States
-
San Carlo di Nancy HospitalLampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy)CompletedBPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsItaly
-
University of BonnPROCEPT BioRoboticsRecruitingBPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsGermany
-
ProVerum MedicalRecruiting
-
Se-cure Pharmaceuticals Ltd.Clalit Health ServicesRecruitingBPH Without Urinary Obstruction and Other Lower Urinary Tract Symptoms (LUTS)Israel
-
Astellas Pharma IncAstellas Pharma Taiwan, Inc.CompletedLower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)Taiwan
-
Robert W. Alexander, MD, FICSTerry, Glenn C., M.D.WithdrawnNocturia | BPH | BPH With Urinary Obstruction | Prostatism | Prostate InflammationUnited States
-
Mansoura UniversityRecruiting
Clinical Trials on Tadalafil
-
Institute for the Study of Urological Diseases,...RecruitingErectile DysfunctionGreece
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedBenign Prostatic HyperplasiaJapan
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownObesity and Erectile DysfuntionMexico
-
Futura Medical Developments Ltd.CompletedErectile DysfunctionUnited States, Bulgaria, Georgia, Poland
-
Saint Petersburg State University, RussiaRecruitingErectile DysfunctionRussian Federation
-
University of PernambucoUnknown
-
Cairo UniversityUnknownErectile DysfunctionEgypt
-
Cedars-Sinai Medical CenterCompleted
-
Regina Elena Cancer InstituteRecruiting